靶向蛋白聚糖的抗体作为非霍奇金淋巴瘤异种移植瘤的标志物
Proteoglycan-targeted antibodies as markers on non-Hodgkin lymphoma xenografts.
作者信息
Kopper L, Bankfalvi A, Mihalik R, Glant T T, Timar J
机构信息
1st Institute of Pathology and Experimental Cancer Research, Semmelweis Medical University, Budapest, Hungary.
出版信息
Cancer Immunol Immunother. 1990;32(2):137-42. doi: 10.1007/BF01754211.
A family of mono- and polyclonal antibodies raised against proteoglycans or their "subcomponents" served as novel markers to characterize the phenotypes of three non-Hodgkin lymphoma xenograft lines (HT 58 lymphoblastic, HT 117 centroblastic, HT 130 centrocytic) together with normal, human peripheral blood B lymphocytes. These xenografted NHL lines, maintained by serial transplantations on artificially immunosuppressed mice, expressed very similar B-cell-related antigens and differences on the cell surface (HT 58 greater than HT 117 greater than HT 130 greater than B cells) when they were exposed to monoclonal antibodies (mAb) to cartilage proteoglycans. Anti-proteoglycan antibodies used in this study recognize complex epitopes of core protein segment associated with carbohydrate, shared by human cartilage proteoglycans and certain lymphoma cells. The binding of these antibodies was independent of cell-cycle phase. The results suggest that the anti-proteoglycan mAbs could be used as new phenotypic markers to individualize non-Hodgkin lymphomas.
针对蛋白聚糖或其“亚组分”产生的一系列单克隆和多克隆抗体，可作为新型标志物，用于表征三种非霍奇金淋巴瘤异种移植细胞系（HT 58淋巴细胞性、HT 117中心母细胞性、HT 130中心细胞性）以及正常人类外周血B淋巴细胞的表型。这些通过在人工免疫抑制小鼠上连续移植维持的异种移植非霍奇金淋巴瘤细胞系，在暴露于抗软骨蛋白聚糖单克隆抗体（mAb）时，表达非常相似的B细胞相关抗原，且细胞表面存在差异（HT 58＞HT 117＞HT 130＞B细胞）。本研究中使用的抗蛋白聚糖抗体识别与碳水化合物相关的核心蛋白片段的复杂表位，这些表位为人软骨蛋白聚糖和某些淋巴瘤细胞所共有。这些抗体的结合与细胞周期阶段无关。结果表明，抗蛋白聚糖单克隆抗体可作为新的表型标志物用于非霍奇金淋巴瘤的个体化诊断。
Zotero 插件